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Introduction: This case report describes an association between an exceptionally rare congenital anomaly and
differentiated thyroid carcinoma. Mayer-Rokitansky-Küster-Hauser syndrome is characterized by vaginal aplasia
associated with other Müllerian duct abnormalities. Its penetrance varies, as does the involvement of other organs.
The association with thyroid carcinoma appears to be exceptionally rare, and warrants further attention.
Case presentation: We present the case of a 19-year-old Caucasian woman with amenorrhea and thyroid disease,
with an unusually late diagnosis of gynecological abnormality. Management of her amenorrhea included
investigation for congenital anomalies, including Mayer-Rokitansky-Küster-Hauser syndrome. Endocrine evaluation
included a detailed analysis of sex hormone levels and thyroid function. The results of a physical examination and
neck ultrasonography revealed abnormalities of the thyroid gland, which led to a diagnosis of thyroid cancer. To
the best of our knowledge, thyroid cancer has not previously been reported in association with Mayer-Rokitansky-
Küster-Hauser syndrome. However, genetic links between Mayer-Rokitansky-Küster-Hauser syndrome and thyroid
cancer have not been investigated. The association may therefore be coincidental.
Conclusions: All women with primary amenorrhea should undergo complete investigation of the genital tract and
the endocrine axis. Careful examination of the thyroid gland is recommended.
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Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is
characterized by vaginal aplasia associated with other
Müllerian duct abnormalities. The severity of the ano-
maly varies, as does the number of involved organs. The
prevalence is one in 5000 women [1]. In type I MRKH
syndrome, there is an isolated absence of the proximal
two-thirds of the vagina. In type II MRKH syndrome,
there are associated malformations including vertebral,
cardiac, urological (upper tract), and otological anoma-
lies [2]. The extent of the vaginal aplasia varies in both
types, ranging from a virtually absent vagina to a short
vagina measuring 2cm to 5cm in length (normal range
8cm to 12cm). Patients have normal development of* Correspondence: doina.piciu@gmail.com
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is usually undetected until the patient is referred for in-
vestigation of primary amenorrhea. This syndrome is im-
portant because it is the second most common cause of
primary amenorrhea, after gonadal pathology. The psy-
chological consequences are severe, even if the anato-
mical defects can be surgically treated. Surgery allows
patients to achieve normal sexual function and even
assisted reproduction.
Case presentation
A 19-year-old Caucasian woman was referred to our
clinic for evaluation of amenorrhea. This was an un-
usually late presentation for the investigation of primary
amenorrhea. She had been investigated for thyroid dys-
function as the presumed cause of her amenorrhea at
the age of 14 years. Her serum thyroid hormone levels
were normal at that time, with thyroid stimulating hor-
mone (TSH) level of 1.4mIU/L (normal range 0.4 tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(normal range 12 to 2.4pmol/L), and no further investi-
gation was undertaken. There was no family history of
thyroid cancer.
We obtained informed consent from our patient for
diagnostic procedures and treatment, as well as consent
for inclusion of her data in an anonymized scientific re-
port. A physical examination showed that development
of sexual characteristics was not entirely normal, al-
though the development of secondary sexual characteris-
tics was normal. Investigations included abdominal and
pelvic ultrasonography and magnetic resonance imaging
(MRI). Type I MRKH syndrome was suspected because
of the total absence of the uterus and fallopian tubes.
She had a vaginal remnant measuring 1.8cm in length.
Both ovaries were normal, and no other structural ab-
normalities were found (Figure 1).
Examination of the thyroid gland showed enlargement,
with a mobile, 2.3cm diameter, solid nodule in the left
lobe. There were multiple mobile left lateral cervical
lymph nodes, with a maximum diameter of 1cm. Thyroid
function testing showed normal serum levels of TSHFigure 1 Pelvic ultrasonography images showing absence of the uter(1.8mIU/L) and anti-thyroid peroxidase antibody
(<34mIU/L). Thyroid ultrasonography showed a hypo-
echoic left thyroid nodule with increased central vascu-
larity. According to the current guidelines for evaluation
of thyroid nodules [3,4], fine needle aspiration biopsy
(FNAB) was indicated. The FNAB showed high cellularity
in the nodule, and cytological examination showed fol-
licular lesions that were classified as Thy3 according to
the latest classification system [5]. Tc-99m pertechnetate
thyroid scintigraphy (185MBq) showed a nodule in the left
lobe with no metabolic activity (‘cold’ nodule) (Figure 2).
The combination of clinical features, cytological examin-
ation findings, and imaging findings led to a diagnosis of
nodular goiter highly suspicious for malignancy. She was
referred to our Surgery Department for total thyroidec-
tomy with selective lymph node dissection.
Pathological examination of the surgical specimen
confirmed a 2.1cm diameter papillary thyroid carcinoma
in the left lobe with invasion of the thyroid capsule.
Three of 16 removed lymph nodes were positive for can-
cer. The cancer was classified as stage I (T2N1aMx)
according to the American Joint Committee on Cancer/us, and the presence of both ovaries.
Figure 2 Tc-99m pertechnetate thyroid scintigraphy showing a
‘cold’ nodule in the left lobe.
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At four weeks after surgery, our patient underwent
radioiodine therapy with a single 3.7GBq (100mCi) dose.
A subsequent iodine 131 whole-body scan (I-131 WBS)
showed minimal residual thyroid tissue in the thyroid
bed (Figure 3A), and no evidence of lymph node or dis-
tant metastases.
Our patient started life-long suppressive hormonal re-
placement with L-thyroxine, 125μg daily. After six weeksFigure 3 Iodine 131 whole body scans. (A) Scan three days after therap
six months after therapy demonstrating negative findings.of treatment, her serum TSH level was 0.083mIU/L, in-
dicating successful suppression of the TSH.
After six months of treatment, we administered two
intra-muscular injections of recombinant human TSH
(rhTSH). At 48 hours after the second injection, her
serum TSH level was >100mIU/L, serum thyroglobulin
(Tg) level was <0.1μg/L (undetectable), and her serum
anti-Tg antibody level was <10kIU/L (negative). I-131
WBS after administration of 185MBq of I-131 was nega-
tive (Figure 3B). She was considered cured of thyroid
cancer, and will undergo long-term follow-up.
Discussion
Müllerian agenesis is a congenital malformation in
women characterized by developmental failure of the
Müllerian ducts, resulting in absence of the uterus and
fallopian tubes, and varying malformations of the upper
part of the vagina. A woman with this condition is hormo-
nally normal, and will therefore develop normal secondary
sexual characteristics at puberty. Her chromosome con-
stellation is 46,XX. The ovaries are present, and ovulation
usually occurs. There are two forms of MRKH: type I
results in isolated absence of the vagina and uterus, and
type II also affects other parts of the body. Among
those with type II, 40 percent have kidney abnormali-
ties (15 percent of this subgroup will have only one kid-
ney), 10 percent will have hearing problems, and 10
percent to 12 percent will have skeletal abnormalities [7].
The association of this condition with endocrine diseasesy, showing minimal residual thyroid tissue in the thyroid bed. (B) Scan
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mined [8].
The cause of MRKH is unknown. Several genes have
been tested to investigate a possible genetic cause, but
no single factor has been identified as responsible for
this condition [7,9]. Treatment consists almost exclu-
sively of surgery, such as uterine and vaginal reconstruc-
tion, and occasionally uterine transplant.
Patients typically have a short vagina, and sexual inter-
course may be difficult and painful. Women with MRKH
usually discover their condition during investigation for
primary amenorrhea. In this situation, most patients are
evaluated for thyroid dysfunction, as some thyroid con-
ditions may impair normal menstruation. Thyroid func-
tion and the reproductive system are connected via the
hypothalamic-hypophyseal-ovarian axis.
Thyroid cancer is the most common endocrine tumor,
and may be aggressive. Although the incidence of this
cancer appears to have increased dramatically over the
last decade [3,4], it is still considered to be rare. Accord-
ing to the European Surveillance of Rare Cancers Project
(RARECARE), a rare cancer is defined as a tumor with
an annual incidence of less than six cases per 100,000
persons [10], and all thyroid cancers fall into this ca-
tegory [3,4,11,12]. Thyroid cancer accounts for 0.5 per-
cent to 1.5 percent of all childhood tumors and is the
most common malignancy of the head and neck in
younger people [13]. An appropriate treatment strategy
can cure this disease, minimize the risk of recurrence,
and result in an excellent prognosis [14].
As thyroid cancer has an incidence of six cases per
100,000 persons and MRHK has an incidence of one per
5000 women, it is emphasized that it is exceptionally
rare for both to occur in the same patient. Both gyneco-
logists and endocrinologists are encouraged to evaluate
the thyroid gland in patients with amenorrhea.Conclusions
All women with amenorrhea should undergo complete
investigation of both the genital tract and the endocrine
system. The association of MRKH with thyroid cancer is
currently considered to be coincidental, but further ge-
netic research is needed to confirm the absence of a com-
mon etiology.Consent
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